vimarsana.com

Latest Breaking News On - தலைமை நிர்வாகி அதிகாரி குறி - Page 4 : vimarsana.com

Delix Therapeutics Retains KCSA Strategic Communications

Delix Therapeutics Retains KCSA Strategic Communications KCSA to provide integrated public and investor relations counsel News provided by Share this article Share this article BOSTON, May 19, 2021 /PRNewswire/ Delix Therapeutics (the Company ), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its agency of record (AOR). KCSA will implement a comprehensive strategic communications program that aims to educate the investment, biopharmaceutical, and patient advocacy communities on Delix s innovative research and mission. KCSA will assist Delix in advancing the understanding of how non-hallucinogenic analogs of psychedelic compounds can be developed into safe, FDA-approved, take-at-home medicines for the treatment of central nervous system-related conditions.

Sundyne s ANSIMAG Pumps Support COVID 19 Vaccine Efforts

Sundyne s ANSIMAG Pumps Support COVID 19 Vaccine Efforts Share Article ANSIMAG Pumps Specified for Use in Pharmaceutical-Grade Freeze Drier Applications Have a Lengthy Track Record of Reliability ANSIMAG Pumps deliver the cooling mediums used to lower product temperatures in freeze drier applications. For years, ANSIMAG pumps have played a key role in pharmaceutical-grade freeze drier applications for vaccines - and today, these applications are more important than ever in the fight against COVID-19. ARVADA, Colo. (PRWEB) March 16, 2021 Sundyne, a global leader in the design and manufacture of mission critical pumps and compressors, announced that its ANSIMAG pumps have been widely deployed in pharmaceutical-grade freeze drier applications used by several companies for vaccines, including COVID-19 vaccines.

Facebook may have vastly overpaid in data privacy settlement - court filing

Article content Facebook Inc may have paid $4.9 billion more than the maximum penalty it faced under a settlement agreement with regulators related to allegations it mishandled user privacy, according to a Wednesday court ruling. The information made public by a Delaware judge who gleaned it from a “white paper” prepared by a law firm advising Facebook’s board of directors as they debated a proposed $5 billion settlement with the Federal Trade Commission. That agreement also protected Chief Executive Officer Mark Zuckerberg. We apologize, but this video has failed to load. Try refreshing your browser, or Facebook may have vastly overpaid in data privacy settlement - court filing Back to video

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.